从植物根际定向批量筛选广谱有机溶剂耐受性脂肪酶产生菌

洋葱伯克霍尔德菌脂肪酶是一类具有重要工业应用价值的优良脂肪酶之一。根据已公布的洋葱伯克霍尔德菌基因组信息, 在传统的洋葱伯克霍尔德菌选择性培养基中添加适量的氨苄青霉素和卡那霉素, 从植物根际的土壤中筛选洋葱伯克霍尔德菌。对获得的单菌落再用含罗丹明B指示剂的产脂肪酶定性检测平板检测, 从4个根际土壤中筛选到35株产脂肪酶的洋葱伯克霍尔德菌, 阳性率达到65%。其中15株对体积浓度为10%的苯、己烷和正庚烷同时具有耐受性。用recA基因分子鉴定上述15株菌种, 全部属于洋葱伯克霍尔德菌菌群。     

耐受有机溶剂洋葱伯克霍尔德菌ZYB002全细胞脂肪酶酶学性质

一株对多种有机溶剂具有良好耐受能力的产脂肪酶菌株ZYB002经分子鉴定为洋葱伯克霍尔德菌。其产生的细胞结合脂肪酶最适温度为65°C,最适pH为8.0,在低于70°C和pH3-8.5的范围内,全细胞脂肪酶保持稳定。Ca2+、K+、Na+和NO3-等离子对脂肪酶活性有激活作用,而Zn2+有抑制效应。全细胞脂肪酶对正丁醇有较强的耐受能力,但曲拉通X-100对脂肪酶活性有强烈的抑制效应。洋葱伯克霍尔德菌ZYB002全细胞脂肪酶良好的碱稳定性、热稳定性和有机溶剂耐受性,表明该全细胞脂肪酶具有重要的工业应用潜力。     

土壤中产脂肪酶洋葱伯克霍尔德菌的分离与鉴定

洋葱伯克霍尔德菌(Burkholderia cepacia)在生物防治、生物降解等农业领域有着广泛的应用,它产生的脂肪酶则在有机合成、精细化工等领域潜力巨大。采用改良的TB-T平板筛选法从土壤中初步筛选出300株洋葱伯克霍尔德菌,然后用脂肪酶活性检测平板对300株菌进行筛选,最终获得6株脂肪酶产量高的菌,通过发酵发现6株菌均有较好的产脂肪酶能力。随后通过16S rDNA比对的方法将6株全部鉴定为B.cepacia。在此基础上,采用HaeⅢ-recA RFLP和基因种特异性PCR对6株菌进行了基因种鉴定,结果表明JWT16、G63YL、WJ158和JWT137属于Burkholderia cenocepacia菌,JWP9属于Burkhold-eria vietnamiensis,JWT267则属于Burkholderia multivorans。     

洋葱伯克霍尔德菌T1828质粒消除方法及条件

采用十二烷基硫酸钠和提高生长温度结合法、紫外线涂布平板法、冻融法、吖啶橙法和黄芩甙提取液消除法等方法消除洋葱伯克霍尔德菌T1828菌株质粒,探讨适合洋葱伯克霍尔德菌质粒消除的方法,并研究最佳质粒消除条件。结果表明十二烷基硫酸钠和提高生长温度结合法最适合于洋葱伯克霍尔德菌T1828质粒消除,同时最佳消除条件为:在T1828培养16 h后加入SDS使其终浓度0.1%,36°C处理18 h,消除率达到49%。筛选到的无质粒突变株可以用于进一步的研究。     

洋葱伯克霍尔德菌临床分离和耐药性监测

/他唑巴坦和复方新诺明敏感.来自ICU的洋葱伯克霍尔德菌耐药更强.结论 洋葱伯克霍尔德菌耐药及多药耐药性严重,应引起广泛关注,尤其是中心ICU,治疗上可选用哌拉西林/他唑巴坦.     

重症监护病房洋葱伯克霍尔德菌肺部感染及耐药性监测

目的 探讨重症监护病房(ICU)洋葱伯克霍尔德菌肺部感染的临床特点及其耐药情况,为临床合理用药提供参考.方法 对2010年10月至2011年10月在ICU住院期间,患者肺部感染洋葱伯克霍尔德菌耐药情况进行回顾性分析.结果 肺部感染患者共检出34株洋葱伯克霍尔德菌,占全部病原菌的1.85％.19种抗菌药物药敏试验结果显示除美罗培南、复方磺胺甲基异噁唑、米诺环素的抑菌活性较高外,其余16种抗菌药物的耐药率高达73.5％～100.0％.结论 洋葱伯克霍尔德菌具有多重耐药性,治疗难度大,应引起足够重视,临床应根据药敏试验结果合理选用抗菌药物.     

2004～2008年洋葱伯克霍尔德菌临床分布和耐药性分析

目的 了解2004年至2008年我院临床分离的洋葱伯克霍尔德菌的标本来源、临床分布和耐药性.方法 采用API staph 鉴定系统和K-B琼脂扩散法,对分离到的55株洋葱伯克霍尔德菌进行鉴定和药敏试验.结果 2004年至2008年共分离出55株洋葱伯克霍尔德菌, 标本来源以痰标本最多(90.91%,50/55),科室分布以ICU最多(60%,33/55),其次为呼吸内科(18.18%,10/55).药敏结果 显示,对多数抗菌药物的耐药率较高,只对美罗培南、哌拉西林/他唑巴坦和亚胺培南的耐药率最低,分别为29.17%、33.33%和39.62%.结论 药敏结果 显示,洋葱伯克霍尔德菌具有高度和多重耐药性,临床抗感染治疗应根据药敏试验结果 选用敏感药物.     

洋葱伯克霍尔德菌致恶性肿瘤患者医院获得性感染的耐药性分析

目的分析我院恶性肿瘤患者医院获得性感染洋葱伯克霍尔德菌的临床特点及对常用抗菌药物的耐药性,为临床合理治疗提供依据。方法回顾性分析2011年1月至2013年12月,从我院恶性肿瘤感染患者送检的细菌培养标本;细菌鉴定用美国BD公司phoenix-100全自动细菌鉴定药敏系统,药敏试验采用纸片法,同时使用WHONET 5.6软件对相关资料进行统计。结果从检测部位分析主要分布在下呼吸道（74.1%）,其次为血液（9.4%）;药敏试验表明139株洋葱伯克霍尔德菌对米诺环素、氯霉素、美罗培南、头孢他啶和头孢哌酮/舒巴坦仍较敏感,可作为临床治疗洋葱伯克霍尔德菌感染的首选药物,其余15种抗菌药物的耐药率高达30.0%~100%。结论洋葱伯克霍尔德菌在恶性肿瘤患者中的耐药现象非常严重,临床应引起高度关注,及早进行微生物学检测,并根据药敏试验结果合理选用抗菌药物。     

儿童医院感染洋葱伯克霍尔德菌三年临床分布特征调查

目的调查三年来儿童医院感染洋葱伯克霍尔德菌的临床分布特点及耐药情况,指导临床合理用药。方法2010年1月-2012年12月住院患儿送检标本采用VITEK-32全自动细菌鉴定仪进行细菌鉴定,药敏试验采用Kirby—Bauer法。结果三年分离到洋葱伯克霍尔德菌分别为28株、36株和51株,共¨5株,呈逐年上升趋势;其来源主要分布在儿童ICU和新生儿病房,以引起儿童呼吸道感染为主要症状;药敏结果显示替卡西林／克拉维酸、庆大霉素、氨苄西林／舒巴坦等耐药率均逐年升高;对哌拉西林／他唑巴坦、头孢他啶和复方新诺明敏感性高。结论儿童医院感染洋葱伯克霍尔德菌呈逐年上升趋势,因其是一种多重耐药菌,天然耐多种抗菌药物,临床监测其分布状况和耐药性具有重要意义。     

洋葱伯克霍尔德菌对哌拉西林/他唑巴坦MIC值变迁的4年监测

目的了解浙江地区4年分离的洋葱伯克霍尔德菌对哌拉西林-他唑巴坦的MIC值变迁,以利于临床对该抗生素在抗感染中更合理的应用。方法先用VITEK-32型配套的药敏检测卡GNS-120检测2000～2003年临床分离的洋葱伯克霍尔德菌对哌拉西林-他唑巴坦的敏感性。对不耐药的菌株进一步用哌拉西林-他唑巴坦E-试条进行MIC检测,并统计其累积的MIC值变化情况。结果2000—2003年,洋葱伯克霍尔德菌对哌拉西林．他唑巴坦的耐药率分别为：40．5％,42．9％,40．6％,41．2％。对分离到不耐哌拉西林．他唑巴坦的100株菌（2000～2003年分别为21株、21株、22株、36株）进行MIC值检测,其累积的MIC百分率,M1C值≤4分别为：47．6％,42．9％,45．5％,36．I％;MIC值≤8分别为：66．7％,52．4％,54．5％,47,2％;MIC值≤16分别为：76．2％,66．7％,63．6％,52．8％。结论4年中临床分离的洋葱伯克霍尔德菌对哌拉西林-他唑巴坦的耐药率虽然变化不大,但其不耐药菌株对哌拉西林-他唑巴坦的累积MIC百分率降低较为明显,表明洋葱伯克霍尔德菌对哌拉西林-他唑巴坦的耐药性存在有增加的趋势,应引起临床的重视。     

Burkholderia cepacia lipase is a promising biocatalyst for biofuel production

Lipases resistant to inhibition and denaturation by methanol are valuable tools for biotechnological applications, in particular for biofuel production. Microbial lipases have attracted a great deal of interest because of their stability at high concentrations of organic solvents. Burkholderia cepacia lipase (BCL) is tested here for robustness towards methanol in terms of conformational stability and catalytic activity in transesterification assays. This lipase turns out to be even more tolerant than the homologous and better characterized enzyme from Burkholderia glumae. BCL unfolding transition, as monitored by far‐UV circular dichroism (CD) and intrinsic fluorescence, displays a T_m above 60°C in the presence of 50% methanol. The protein unfolds at low pH, and the organic solvent affects the nature of the denatured state under acidic conditions. The protein performs well in transesterification assays upon prolonged incubations at high methanol concentrations. BCL is highly tolerant to methanol and displays particularly high conformational stability under conditions employed for transesterification reactions. These features depict BCL as a promising enzyme for biofuel industry.     

Kinetic resolution of (+/-)-1-phenylethanol in [Bmim][PF6] using high activity preparations of lipases

Lipases from two different sources Candida rugosa (CRL) and Burkholderia cepacia (BCL) were formulated as enzyme precipitated and rinsed with organic solvents, organic solvent rinsed enzyme preparation, cross-linked enzyme aggregates (CLEAs) and protein coated micro-crystals (PCMCs). These various enzyme formulates were evaluated for the kinetic resolution of (+/-)-1-phenylethanol in ionic liquid [Bmim][PF(6)] by transesterification with vinyl acetate. Of all the enzyme forms evaluated EPRP and PCMC in the case of CRL showed the best results with 26 % (E value=153) and 53% (E value=79) conversion, respectively, at 35 degrees C in 24h. Carrying out this conversion with PCMC at lower temperature of 25 degrees C further improved the E value to 453 (with 44% conversion in 12h). For BCL the acetone-rinsed enzyme preparation (AREP), CLEA and PCMC performed equally well with % conversion of 50 and 99 ee(p) (%) (E value >1000) in just 2h, whereas, the free lipase gave only 8% conversion.     

GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl

BCL2L12 has been reported to be involved in post-mitochondrial apoptotic events in glioblastoma, but the role of BCL2L12A, a splicing variant of BCL2L12, remains unknown. In this study, we showed that BCL2L12 and BCL2L12A were overexpressed in glioblastoma multiforme (GBM). Large-scale yeast two-hybrid screening showed that BCL2L12 was a GSK3b binding partner in a testis cDNA library. Our data demonstrated that GSK3b interacts with BCL2L12 but not BCL2L12A, whose C terminus lacks a binding region. We found that a BCL2L12_153–191 fragment located outside of the C-terminal BH2 motif is responsible for GSK3b binding. In contrast, no interaction was detected between BCL2L12A and GSK3b. In vitro kinase and l-phosphatase assays showed that GSK3b phosphorylates BCL2L12 at S156, while this site is absent on BCL2L12A. Moreover, our data also showed that the BCL2L12_153–191 fragment directly interrupted GSK3bmediated Tau phosphorylation in a dose-dependent manner. Ectopic expression of GFP-fused BCL2L12 or BCL2L12A in U87MG cells leads to repression of apoptotic markers and protects against staurosporine (STS) insults, indicating an antiapoptotic role for both BCL2L12 and BCL2L12A. In contrast, no anti-apoptotic ability was seen in BCL2L12(S156A). When BCL2L12-expressing U87MG cells were co-administrated with STS and LiCl, cells underwent apoptosis. This effect could be reversed by LiCl. In short, we established a model to demonstrate that GSK3b interacts with and phosphorylates BCL2L12 and might also affect BCL2L12A to modulate the apoptosis signaling pathway in glioblastoma. These findings suggest that LiCl may be a prospective therapeutic agent against GBM.     

Cloning of the bovine antiapoptotic regulator, BCL2-related protein A1, and its expression in trophoblastic binucleate cells of bovine placenta

This report studied the identification and sequence of a full-length cDNA for the bovine BCL2 antiapoptotic family member, BCL2-related protein A1 (BCL2A1), and its localized and quantitative expression in the placenta to clarify the regulatory mechanism of trophoblast cell proliferation and differentiation during implantation and placental development. We cloned a full-length bovine BCL2A1 cDNA with 725 nucleotides and an open-reading frame corresponding to a protein of 175 amino acids. The predicted amino acid sequence shared 78% homology with human BCL2A1. All BCL2 homology domains (BH1, BH2, BH3, and BH4) in bovine BCL2A1 were conserved as well as in other mammalian BCL2A1. In the placentomes, in situ hybridization demonstrated that the BCL2A1 was limited in binucleate cells expressing various pregnancy-specific molecules like placental lactogen. BCL2-associated X protein (BAX) was also expressed in binucleate cells. Quantitative real-time RT-PCR detection exhibited a high-level expression of BCL2A1 in the conceptus at Day 21 of gestation, and it was expressed and increased in the extraembryonic membrane, cotyledon, and intercotyledon from implantation to term. BAX expression intensity increased with progression of gestation and remained elevated in postpartum. Caspase-3 protein (CASP3) and mRNA (CASP3) were detected from late gestation to postpartum in placenta as well as in the results of TUNEL detection. We believe that the apoptosis of binucleate cells may be regulated by the balance of the BCL2A1 and BAX. BCL2A1 genes produced a BCL2A1 protein in the mammalian cell-expression system. This molecule is a new candidate for antiapoptotic maintenance of the binucleate cells that support placental functions throughout gestation in bovine.